Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight rating and announces Price Target of $110.
As of April 8, 2024, four stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.